ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

AACR’s First Special Conference Scheduled for Oct. 23-27 at Cape Cod

July 22, 1988

In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online

February 5, 1999

Half Of Mexican-Origin Women With Breast Cancer Diagnosed Before Age 50, Study Finds

September 24, 2010

UICC Names Banker As Chief Executive

September 11, 2009

President Proposes $1 Billion Increase For NIH In FY2011; Cancer A High Priority

February 5, 2010

Also M.D. Anderson awarded three new, one renewal SPORE grant.

October 31, 2003